Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

We embrace diversity across all dimensions and levels of the organization, and we strive to ensure every employee is supported in reaching their full potential. We hire motivated people with diverse backgrounds, identities, experiences and skillsets. We are committed to fostering an inclusive culture where all employees feel valued, respected and empowered to create value for patients.

Position Summary

The Principal, Biostatistician will own the statistical and quantitative work that connects clinical evidence to the most important decisions Roivant makes across its pipeline. This is not a strategy role — this is a figure-things-out and get-things-done role in a high-stakes environment with substantial ownership. We expect you to get to ground truth on the hardest clinical and scientific questions the company faces, working directly in trial datasets and translating rigorous analysis into recommendations that leadership acts on.

The Principal will pressure-test the clinical assumptions underpinning key pipeline and commercial decisions, build the statistical frameworks needed to evaluate evidence across assets, and ensure Roivant has a clear-eyed view of what its data shows. The scope is intentionally broad and is well-suited to a high-potential individual earlier in their career with exceptional upside and a strong desire to take on responsibility.

Responsibilities

Clinical Trial Data & Signal Detection

Work directly in ongoing and completed clinical trial datasets (CSRs, patient-level data, interim readouts) to identify efficacy signals, safety patterns, and subgroup effects that inform go/no-go and commercialization decisions
Build rigorous statistical analyses from scratch: mixed-effects models, longitudinal models, Bayesian frameworks, subgroup analyses, and sensitivity analyses across Roivant's pipeline assets
Monitor emerging safety signals and unexpected findings in real time across ongoing studies; surface and contextualize them for leadership before they become surprises
Pressure-test clinical assumptions: challenge endpoint choices, scrutinize statistical analysis plans, and flag where the data does not support the narrative
Execute focused 1-5 day analytical sprints on the highest-priority questions from Roivant and Vant leadership

Evidence Synthesis & Competitive Intelligence

Develop a deep, differentiated read of the clinical evidence base for Roivant's near-commercial assets: what the data shows, what it does not, and where the science is genuinely uncertain
Analyze competitors' trial data, published and unpublished, with the same rigor applied to Roivant's own: endpoints, patient populations, effect sizes, and durability
Synthesize findings from literature, registries, claims, and proprietary datasets into coherent evidence narratives that hold up under scrutiny

Data Infrastructure & Cross-Platform Work

Drive selection and integration of the data sources needed to support portfolio decisions, including claims, labs, clinical trial data, and genomics
Help build shared analytical infrastructure across Roivant and Vant companies
Identify opportunities to apply consistent statistical frameworks across assets and therapeutic areas

Qualifications

Advanced degree in biostatistics, statistics, epidemiology, or a closely related quantitative field; direct experience in clinical trial statistics strongly preferred
Hands-on fluency with clinical trial data; you have worked directly in patient-level datasets, not just read summaries of analyses others ran
Deep command of statistical methods used in clinical development: mixed-effects models, longitudinal and repeated-measures analyses, Bayesian approaches, multiplicity adjustment, and sensitivity analyses
Familiarity with clinical trial design and regulatory statistical frameworks (ICH E9, estimands, SAP development)
Track record of translating rigorous analysis into decisions; your numbers have changed something
Able to present complex statistical findings clearly to non-technical audiences, including CEO-level stakeholders
Intensely curious, resourceful, and motivated; you run toward hard, ambiguous problems

Context

Roivant is preparing to become the next breakout commercial-stage biotech, with the commercialization of brepocitinib, IMVT-1402, and mosliciguat. Getting those launches right requires an unusually rigorous understanding of the clinical evidence that defines each market: what the data actually shows, not what anyone wishes it showed.

This role ensures that understanding exists. It carries real ownership, direct exposure to senior leadership, and a trajectory that can serve as a foundation for future senior roles across the platform.

Compensation & Benefits

This is a full-time position. The role offers meaningful equity participation and a comprehensive company-sponsored benefits package.

Base salary will be determined during the interview process and will vary based on multiple factors, including prior experience, relevant expertise, current business needs, and market conditions. The expected base salary will generally be between $130,000 to $220,000 per year at commencement of employment, but the final salary offered may be outside this range based on individual circumstances.

This position is at-will and Roivant reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance and business and market conditions.

Roivant Sciences provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.

We will not accept unsolicited resumes nor outreach from agencies. Please do not send agency resumes to our website or Roivant Sciences and affiliated employees. Thanks!

About the company

Roivant Sciences develops and delivers medicines, with a focus on genetic disorders and RNA therapeutics, using in-house R&D plus strategic partnerships. Its subsidiary Genevant uses proprietary delivery platforms to create RNA-based treatments, including mRNA, RNA interference, and gene editing. Revenue comes from developing drug candidates, licensing deals, partnerships, and selling approved drugs, leveraging collaborations to accelerate the pipeline. The goal is to bring effective medicines to patients faster and more efficiently by combining technology platforms with strategic alliances.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2014

Get referred to Roivant Sciences

See people who can refer or advise you

Simplify's Take

What believers are saying

Moderna paid $950 million in July 2026, strengthening Roivant’s cash and buyback capacity.
Brepocitinib now has U.S. commercialization, plus Phase 3 uveitis and sarcoidosis catalysts in 2026.
Roivant holds roughly $4 billion cash, funding launches, trials, and a $1 billion repurchase program.

What critics are saying

LISRAYA’s launch depends on reimbursement, prescriber adoption, and steroid-sparing data translating into sales by 2027.
IMVT-1402 and mosliciguat remain clinical bets; failure in 2026 readouts cripples the pipeline.
Insider sales topped $100 million in 90 days, and valuation bakes in flawless execution.

What makes Roivant Sciences unique

Roivant’s Vant structure isolates programs, speeds decisions, and concentrates capital on late-stage assets.
LISRAYA launched August 27, 2026, becoming the first targeted dermatomyositis therapy.
Roivant couples biotech development with a litigation engine, monetizing Genevant’s LNP patents.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

-1%

2 year growth

GlobeNewswire

Sep 6th, 2026

Roivant to present topline results from the Phase 2 PHocus study of mosliciguat in patients with Pulmonary Hypertension associated with interstitial lung disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and host investor call. September 06, 2026 01:00 ET | Source: Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) - Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at www.investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call. About Roivant Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes LISRAYA(TM)(brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com. Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

PR Newswire

Aug 28th, 2026

Orsini partners with Priovant for first FDA-approved targeted dermatomyositis therapy LISRAYA

Orsini has been named a specialty pharmacy partner for Priovant's LISRAYA (brepocitinib), the first FDA-approved targeted therapy for dermatomyositis. The once-daily oral treatment is designed for adults with this rare autoimmune inflammatory disease. Dermatomyositis causes painful skin rashes, muscle weakness, and systemic complications including lung and cardiac disease. LISRAYA was tested in VALOR, the largest placebo-controlled dermatomyositis trial conducted, where patients showed improvement across disease measures including muscle strength and functional disability. "The approval of LISRAYA represents an incredible step forward for these patients," said Orsini CEO Brandon Tom. Priovant's Chief Operating Officer Daniel Herz-Roiphe noted the approval brings new hope to a population with previously limited treatment options. Orsini has provided rare disease pharmacy solutions since 1987.

EMJ Reviews

Aug 28th, 2026

FDA approves first-in-class drug for rare skin disease.

FDA approves first-in-class drug for rare skin disease. Key summary: * FDA approves Lisraya (brepocitinib) as the first targeted therapy for adults with dermatomyositis. * The drug reduced or eliminated the need for steroid treatment in some patients during trials. * Analysts forecast more than $2bn in annual sales for brepocitinib in dermatomyositis alone. The FDA has approved a new drug from Roivant and partner Priovant Therapeutics for the treatment of a rare skin and muscle condition for use in the US. Lisraya (brepocitinib), to be taken as a once daily pill, will now be available to patients with dermatomyositis (DM), a systemic autoimmune condition that causes painful skin rashes and legions, progressive muscle weakness and can severely affect quality of life if left untreated. First targeted therapy for DM. Brepocitinib is a first-in-class TYK2/JAK1 inhibitor, which works by blocking harmful inflammatory proteins, and is currently the first and only targeted therapy approved for dermatomyositis. The drug performed well in a late-stage trial last year, showing improvement in both skin and muscle symptoms in DM patients, reducing or stopping the need for steroids that are commonly used as a treatment for the disease but can cause long-term side effects. Based on the myositis Total Improvement Score, benefits were seen as early as 4 weeks into the trial, increased over time and were sustained until the end of the study, with brepocitinib achieved a final mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for placebo. A rise in valuation for Roivant. The drug's approval marks significant progress for treatment of the disease, for which there are no currently other specific treatments and patients have had to rely on non-targeted drugs. Ben Zimmer, Chief Executive Officer of Priovant, said: "I am thrilled that adults with dermatomyositis finally have a fundamentally new treatment option - one specifically designed to target the biology of their disease and shown to meaningfully improve how patients feel and function in their daily lives." Ruth Ann Vleugels, MD, MPH, MBA, a leading expert in autoimmune connective tissue diseases and emerging therapies, said: "Dermatomyositis affects nearly every aspect of a patient's life, causing physical disability, disfiguring skin disease, pain, itch, and a profound loss of independence and sense of self." "The approval of Lisraya (brepocitinib) marks a turning point for patients living with dermatomyositis," she added. Following the approval announcement, Roivant shares closed up 2% on Thursday, putting its market value at roughly $27.1bn. That valuation has risen dramatically over the past year. Analysts predict annual sales of more than $2 billion for brepocitinib in dermatomyositis alone by the early 2030s. Press play to listen to this content

MarketBeat

Aug 28th, 2026

Roivant Sciences (NASDAQ:ROIV) stock price down 6.4% - Here's what happened.

Roivant Sciences (NASDAQ:ROIV) stock price down 6.4% - Here's what happened. August 28, 2026 Key points. * Roivant Sciences shares fell 6.4% to $35.17 in mid-day trading, with volume 71% below the stock's average daily activity. * The FDA approved and Roivant launched LISRAYA (brepocitinib), described as the first targeted and oral treatment for adult dermatomyositis. The drug carries a U.S. list price of $35,000 per 30-day supply, though commercial success will depend on reimbursement, adoption and launch execution. * Analysts remain broadly positive, with a consensus "Moderate Buy" rating, while Roivant continues to be unprofitable and insiders have sold roughly 2.86 million shares worth $100.1 million over the past 90 days. * Interested in Roivant Sciences? Here are five stocks we like better. Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) fell 6.4% during mid-day trading on Friday. The company traded as low as $35.17 and last traded at $35.17. 1,707,108 shares were traded during trading, a decline of 71% from the average daily volume of 5,890,813 shares. The stock had previously closed at $37.58. Key stories impacting Roivant Sciences. Here are the key news stories impacting Roivant Sciences this week: * The FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, a rare inflammatory disease affecting the skin and muscles. The once-daily oral treatment is described as the first targeted therapy - and first oral drug - for the condition, giving Roivant and partner Priovant a potentially differentiated product in an underserved market. * LISRAYA is now available in the United States, allowing Roivant and Priovant to begin generating commercial revenue rather than relying solely on pipeline milestones. The launch price is $35,000 for a 30-day supply, supporting the possibility of substantial revenue per treated patient, subject to insurance coverage, patient access and adoption. * HC Wainwright reaffirmed its Buy rating and set a $41 price target, implying roughly 14.7% upside from the cited $35.76 reference price. The endorsement may reinforce investor confidence in LISRAYA's commercial opportunity. * The approval removes a significant regulatory risk, but investors will likely focus next on prescription volume, reimbursement, launch costs and how economics are shared with Priovant and Pfizer. Roivant remains unprofitable, so commercial execution will be important to justify its valuation. Wall Street analyst weigh in. A number of equities research analysts have weighed in on ROIV shares. Citigroup raised their price target on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, May 21st. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14. Discover more Trading Financial Derivatives investment Roivant Sciences stock performance. The company has a market cap of $25.79 billion, a PE ratio of -67.38 and a beta of 1.12. The business's 50-day moving average is $35.09 and its 200 day moving average is $30.88. Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Equities research analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year. Insider buying and selling. In related news, insider Mayukh Sukhatme sold 144,756 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at $679,649,358.72. This represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $56,376,551.85. The trade was a 11.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,855,913 shares of company stock worth $100,107,258. Insiders own 8.80% of the company's stock. Institutional trading of Roivant Sciences. Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. grew its holdings in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its holdings in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in Roivant Sciences during the 4th quarter valued at $47,000. Parallel Advisors LLC raised its holdings in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock valued at $59,000 after buying an additional 2,665 shares during the period. Institutional investors own 64.76% of the company's stock. Roivant Sciences company profile. Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as "Vants." Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines. The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Roivant Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list. While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Associated Press

Aug 27th, 2026

FDA approves Roivant's LISRAYA for dermatomyositis, first major therapeutic innovation in decades

Roivant announced that the US Food and Drug Administration has approved LISRAYA (brepocitinib) for treating adults with dermatomyositis, a rare autoimmune disease. The once-daily pill is the first targeted therapy approved for the condition and is now available in the US. LISRAYA is a first-in-class TYK2/JAK1 inhibitor shown to improve skin disease, muscle strength, and physical function whilst reducing steroid dependency. The approval follows the Phase 3 VALOR trial, the largest dermatomyositis clinical trial ever conducted. In the trial, 55% of patients treated with LISRAYA achieved moderate or better improvement and minimal steroid use by the end of the 52-week study, compared to 30% on placebo. Among patients taking higher doses of corticosteroids at baseline, 62% tapered to minimal or no steroid use. Eligible patients may pay as little as $0 per month through the LISRAYA My Compass Support programme.

Roivant Sciences

Principal Biostatistician

About the job

About the company

Get referred to Roivant Sciences

Simplify's Take

What believers are saying

What critics are saying

What makes Roivant Sciences unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth